We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Axol Bioscience

Axol Bioscience supports your pursuit of more effective, safer therapies. They use induced pluripotent stem cells (iPSCs) to build more relevant models of human disease to expand your understanding and de-risk drug development.

Latest Content

Fluorescent microscopy image of motor neurons, microglia, and astrocytes in triculture.

Initiative Expands Stem Cell Models for ALS Research

A global initiative builds a diverse panel of ALS stem cell models, improving understanding of disease variability, enhancing drug discovery, and supporting more effective therapeutic development.

The Use of Human iPSC-derived Cells in Disease Modeling content piece image

The Use of Human iPSC-derived Cells in Disease Modeling

Speaking at the Innovations in Disease Modeling online symposium, Steven Broadbent delivered his talk on the use of human iPSC-derived cells in disease modeling.

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes To Help Improve Drug Discovery content piece image

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes To Help Improve Drug Discovery

Axol Bioscience Ltd. has announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter